Business Context and Reporting Period
Company: Intensity Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 11, 2025 (Event Date)
Reporting Period: Specific event reporting for a capital raise transaction closed on June 13, 2025.
Key Financial Metrics
This filing reports a specific equity financing event rather than periodic financial performance metrics (e.g., revenue, profit, or operating cash flow). The filing text does not provide a clear value for revenue, profit, margins, or existing debt levels.
| Metric | Value |
|---|---|
| Firm Shares Sold | 6,675,000 |
| Over-Allotment Shares Exercised | 1,001,250 |
| Total Shares Sold | 7,676,250 |
| Public Offering Price | $0.30 per share |
| Net Proceeds | Approximately $1.9 million |
| Representative's Warrants Issued | 383,812 (5% of total shares) |
| Warrant Exercise Price | $0.375 per share |
Material Changes
- Capital Structure: The Company completed a public offering of common stock, increasing its share count by 7,676,250 shares.
- Liquidity: The transaction generated approximately $1.9 million in net proceeds after underwriting discounts and estimated offering expenses.
- Dilution: The issuance includes 383,812 unregistered warrants granted to the underwriter (ThinkEquity LLC) as compensation, exercisable at $0.375 per share.
Guidance, Outlook, and Use of Proceeds
Management intends to utilize the net proceeds for the following specific purposes:
- INVINCIBLE-4 Study: Patient enrollment and reaching data readout (expected in the first half of 2026).
- INVINCIBLE-3 Study: Treatment of existing patients, including drug product supply, database maintenance, safety monitoring, and pharmacovigilance.
- General Corporate: Working capital and general corporate purposes.
Risks and Contingencies: The filing includes standard forward-looking statements regarding the amount of proceeds and the timing of study data readouts. Actual results may differ due to risks detailed in the Company's Form 10-K and the Prospectus Supplement.
Investor Verification Checklist
- Verify the final closing date of the offering (June 13, 2025) and the full exercise of the over-allotment option.
- Confirm the exact net proceeds received ($1.9 million) against the gross proceeds calculated from the share count and price.
- Review the terms of the Representative's Warrants (Exhibit 4.1) regarding the cashless exercise feature and registration rights.
- Monitor the progress of the INVINCIBLE-4 and INVINCIBLE-3 studies as the primary use of funds.
- Check subsequent filings for any updates on the Company's cash runway given the biotech sector's capital intensity.